U.S. markets closed

CV Sciences, Inc. (CVSI)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.5650-0.0380 (-6.30%)
At close: 3:59PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.6030
Open0.5990
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.5101 - 0.6100
52 Week Range0.2500 - 1.2700
Volume931,338
Avg. Volume1,368,821
Market Cap56.511M
Beta (5Y Monthly)0.95
PE Ratio (TTM)N/A
EPS (TTM)-0.1980
Earnings DateNov 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.92
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • CV Sciences, Inc. Announces Launch of ProCBD™ Product Line
    GlobeNewswire

    CV Sciences, Inc. Announces Launch of ProCBD™ Product Line

    Clinical Strength ProCBD™ is Supported by Clinical Research and Available Exclusively Through Health Practitioners CV Sciences, Inc. Announces Launch of ProCBD™ Product Line Clinical Strength ProCBD™ is supported by clinical research and available exclusively through health practitioners.SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp derived cannabidiol (CBD) products, today announced the launch of ProCBD™, a full product line of clinical strength CBD products available exclusively through health practitioners.Clinical strength ProCBD™ products were created with the CV Sciences Medical Advisory Board specifically to meet patient needs and to fit seamlessly with existing care plans. ProCBD™ is the only CBD supported by published investigations, randomized controlled trial, and post marketing safety review.Formulated with CV Sciences’ decarboxylated and distilled hemp extract for concentrated CBD levels that are best used under a specialist’s care, ProCBD™ is available in Roll-On, Liquids and Softgels. The ProCBD™ product line is non-GMO, gluten free, plant-based and vegan friendly.“As the only clinical strength CBD on the market supported by multiple research studies, we believe ProCBD™ has tremendous potential in the professional healthcare channel,” said Joseph Dowling, Chief Executive Officer of CV Sciences. “The use of alternative medicine is becoming increasingly prevalent as consumer preferences continue to shift toward natural, plant-based remedies for a range of medical conditions. We are excited to launch ProCBD™ and partner with medical professionals seeking science-based, natural alternatives to provide to their patients.”About CV Sciences, Inc.CV, or Curriculum Vitae, is Latin for “course of life”, and science is the pursuit of truth. CV Sciences: our name is our mission -- improving quality of life through nature and science.CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based dietary supplements and CBD products to a range of market sectors; and a drug development division focused on developing and commercializing CBD-based novel therapeutics. The Company’s PlusCBD™ products are sold at more than 6,200 retail locations throughout the U.S. and it is the top-selling brand of hemp-derived CBD on the market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry.  CV Sciences follows all guidelines for Good Manufacturing Practices (GMP) and the Company’s products are processed, produced, and tested throughout the manufacturing process to confirm strict compliance with company standards and specifications.  With a commitment to science, PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov.  PlusCBD™ was the first hemp CBD supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. CV Sciences, Inc. has primary offices and facilities in San Diego, California.  Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.FORWARD-LOOKING DISCLAIMERThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.CONTACT INFORMATION: Investor Contact: ICR Scott Van Winkle 617-956-6736 scott.vanwinkle@icrinc.comMedia Contact: ICR Cory Ziskind 646-277-1232 cory.ziskind@icrinc.comA photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2e055ef7-e738-48a7-90a3-dfa536005a6a

  • CV Sciences, Inc. Receives Nutritional Outlook’s 2020 Best of the Industry Award
    GlobeNewswire

    CV Sciences, Inc. Receives Nutritional Outlook’s 2020 Best of the Industry Award

    SAN DIEGO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, announced today that it received Nutritional Outlook’s 2020 Best of the Industry Awards, in the Retail brand/product category. CV Sciences was recognized for setting the stage in 2020 to show how hemp-derived CBD companies can not only secure a mainstream audience but also charter a new course outside of the CBD category. In 2020, CV Sciences launched a powerful pair of non-CBD immune supporting products: CV™ Defense and CV™ Acute, which opened markets and sales channels for the Company, including major e-commerce retailers not currently accessible by CBD-based products. Both are made with the same rigorous manufacturing and testing standards CV Sciences is known for.“Congratulations to all of the 2020 Best of the Industry Award winners,” said Mike Hennessy Jr., president and CEO of MJH Life Sciences™, the parent company of Nutritional Outlook®. “Each winner raised the bar for excellence in its own way. Thanks to their trailblazing achievements in 2020, this year’s winners will help shape, for the better, the state of the natural product, dietary supplement, and food and beverage industries for years to come.”Nutritional Outlook® is the industry’s leading multimedia resource for manufacturers of dietary supplements, healthy foods and beverage. Their 2020 Best of the Industry Awards recognizes individuals, groups, and companies whose initiatives in 2020 set a new standard for excellence and positively influenced the natural product, dietary supplement, and food and beverage industries. Best of the Industry Award winners are selected by Nutritional Outlook®’s esteemed editors based on their survey of market achievements.“We are honored to receive this recognition for our commitment to building consumer confidence and trust in the safety and quality of our products,” said Joseph Dowling, Chief Executive Officer of CV Sciences. “We look forward to continuing to innovate in 2021 and bringing additional products to market that improve quality of life through nature and science.”About CV Sciences, Inc. CV, or Curriculum Vitae, is Latin for "course of life", and science is the pursuit of truth. CV Sciences: our name is our mission -- improving quality of life through nature and science.CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based dietary supplements and CBD products to a range of market sectors; and a drug development division focused on developing and commercializing CBD-based novel therapeutics. The Company’s PlusCBD™ products are sold at more than 6,200 retail locations throughout the U.S. and it is the top-selling brand of hemp-derived CBD in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences follows all guidelines for Good Manufacturing Practices (GMP) and the Company’s products are processed, produced, and tested throughout the manufacturing process to confirm strict compliance with company standards and specifications. With a commitment to science, PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. PlusCBD™ was the first hemp CBD supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. CV Sciences, Inc. has primary offices and facilities in San Diego, California. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.Forward Looking Statements This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risk and uncertainties.Contact Information Investor Contact: ICR Scott Van Winkle 617-956-6736 scott.vanwinkle@icrinc.com Media Contact: ICR Cory Ziskind 646-277-1232 cory.ziskind@icrinc.com

  • CV Sciences, Inc. Announces Closing of Committed Equity Financing Transaction
    GlobeNewswire

    CV Sciences, Inc. Announces Closing of Committed Equity Financing Transaction

    SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it has entered into a Common Stock Purchase Agreement with Tumim Stone Capital, LLC (the “Investor”). Pursuant to the Stock Purchase Agreement, the Company has the right, subject to certain conditions, to issue and sell to the Investor from time to time up to $10 million of the Company’s Common Stock registered under the Company’s Form S-3 Registration Statement dated April 21, 2020, as supplemented by a prospectus supplement to be filed by the Company with the Securities and Exchange Commission.   The Common Stock Purchase Agreement provides, among other things, that the Company may direct, every three trading days, the Investor to purchase a number of shares not to exceed an amount determined based upon the trading volume and stock price of the Company’s shares.   The specific terms of the financing are set forth in the full text of the Common Stock Purchase Agreement, which will be filed in its entirety with the Company’s Current Report on Form 8-K reporting the transaction. The Company remains on track to achieve cashflow break-even by mid 2021. The Company expects to use net proceeds from the financing over time for general corporate purposes which may include, without limitation, funding of product development, sales and marketing activities, increasing the Company’s working capital and investment in its products and intellectual property in order to accelerate growth.The information contained in this press release shall not constitute an offer to sell or the solicitation of an offer to buy the shares of the Company’s Common Stock discussed herein, nor shall there be any offer, solicitation or sale of the shares in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.About CV Sciences, Inc. CV, or Curriculum Vitae, is Latin for "course of life", and science is the pursuit of truth. CV Sciences: our name is our mission -- improving quality of life through nature and science.CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based dietary supplements and CBD products to a range of market sectors; and a drug development division focused on developing and commercializing CBD-based novel therapeutics. The Company’s PlusCBD™ products are sold at more than 6,200 retail locations throughout the U.S. and it is the top-selling brand of hemp-derived CBD in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences follows all guidelines for Good Manufacturing Practices (GMP) and the Company’s products are processed, produced, and tested throughout the manufacturing process to confirm strict compliance with company standards and specifications. With a commitment to science, PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. PlusCBD™ was the first hemp CBD supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. CV Sciences, Inc. has primary offices and facilities in San Diego, California. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.Forward Looking Statements This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risk and uncertainties.Contact Information Investor Contact: ICR Scott Van Winkle 617-956-6736 scott.vanwinkle@icrinc.comMedia Contact: ICR Cory Ziskind 646-277-1232 cory.ziskind@icrinc.com